Trelegy Ellipta
Fluticasone/Umeclidinium/Vilanterol
Why Trelegy Ellipta Costs $380.00 Per Claim
Trelegy Ellipta (Fluticasone/Umeclidinium/Vilanterol) is used to treat asthma/copd. According to CMS Medicare Part D spending data, the program spent $2.9B on this drug, covering 865,000 beneficiaries across 7,560,000 claims.
This drug is currently protected by patents expiring Sep 26, 2030. Until patent protection ends, no generic version can enter the market, which limits price competition. Once generics become available, the price typically drops 80-95%.
Spending on Trelegy Ellipta increased by +19.8% year-over-year, driven by increased utilization among Medicare beneficiaries.
Price Breakdown
Drug Details
Frequently Asked Questions
Trelegy Ellipta (Fluticasone/Umeclidinium/Vilanterol) costs an average of $380.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $3,325.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.
Trelegy Ellipta averages $380.00 per Medicare Part D claim — roughly equivalent to a 30-day supply for most patients on standard dosing. Without insurance, expect higher cash-pay prices unless you use a discount program (GoodRx, SingleCare, manufacturer copay assistance). With Medicare or commercial insurance, your out-of-pocket cost depends on your plan's formulary tier and deductible status.
A typical 30-day supply of Trelegy Ellipta reflects in our Medicare Part D average of $380.00 per claim. No generic is available yet, so cost remains at brand-name pricing. Cash-pay prices vary by pharmacy — comparison shopping (or using GoodRx coupons) often saves 20-50% off the listed price.
Most commercial insurance plans and Medicare Part D plans cover Trelegy Ellipta, but coverage varies by formulary tier. Trelegy Ellipta is often Tier 2 or Tier 3 on most formularies, meaning a higher copay than generic alternatives. Some plans require prior authorization or step therapy. Check your plan's formulary or call the number on your insurance card to confirm.
Several options for cash-pay patients: (1) Manufacturer patient assistance programs — the manufacturer may offer copay cards or free-drug programs for income-qualified patients; (2) Discount programs like GoodRx, SingleCare, or RxSaver typically save 20-80% off the cash price; (3) Mark Cuban's Cost Plus Drugs offers transparent generic pricing if a generic is available; (4) 340B-eligible community health centers offer drugs at federally negotiated discounts. Patient assistance programs are the primary affordability path while no generic is available.
Trelegy Ellipta is still under patent protection until Sep 26, 2030, giving the manufacturer market exclusivity. Once the patent expires, generics enter the market and prices typically fall 80-95% within 1-2 years.
No, Trelegy Ellipta is currently brand-only. Patent protection expires Sep 26, 2030, after which generic versions may enter the market.
Medicare Part D spent $2.9B on Trelegy Ellipta, covering 865,000 beneficiaries across 7,560,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.
Check manufacturer patient assistance programs for potential savings. You can also compare prices at different pharmacies, use prescription discount programs (GoodRx, SingleCare, Cost Plus Drugs), or ask your doctor about therapeutic alternatives in the same drug class.
The this entity record above pulls directly from CMS Medicare Part D Drug Spending data. What follows is the per-entity context — how this entity sits in the broader U.S. Medicare prescription-drug pricing distribution and which underlying factors drive the headline numbers.
Every number on this page links back to CMS Medicare Part D Drug Spending data; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. prescription drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.
Related
Compare costs for other asthma/copd medications
Compare 10 drugs in the Asthma & COPD Inhalers class
See every GlaxoSmithKline drug tracked by Medicare Part D
Top prescription drugs by Medicare spending
Drugs losing patent protection soon
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.